We read with interest the original article by Pomej et al, which was recently published
in Digestive and Liver Disease [
[1]
]. In a large, retrospective cohort of clinically stable patients with cirrhosis, these
Authors demonstrated that a “substantially elevated” level of von Willebrand factor
antigen (i.e.: >420%) was predictive of hepatic decompensation and liver-related mortality
independently of age, etiology of liver disease, Child-Pugh stage, severity of portal
hypertension, serum creatine, and C-reactive protein [
[1]
].Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Digestive and Liver DiseaseAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Clinical significance of substantially elevated von Willebrand factor antigen levels in patients with advanced chronic liver disease.Dig Liver Dis. 2022; 54: 1376-1384https://doi.org/10.1016/j.dld.2022.06.010
- Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension.Gut. 2011; 60: 1133-1138
- Noninvasive risk stratification after HCV eradication in patients with advanced chronic liver disease.Hepatology. 2021; 73: 1275-1289
- Decreasing von Willebrand factor levels upon nonselective beta blocker therapy indicate a decreased risk of further decompensation, acute-on-chronic liver failure, and death.Clin Gastroenterol Hepatol. 2022; 20 (e1366): 1362-1373
- Quantification of exceedingly high levels of von Willebrand factor in cirrhosis: next upgrading of the MELD-Na score?.Dig Liver Dis. 2022; 54: 1374-1375https://doi.org/10.1016/j.dld.2022.07.009
- Von-Willebrand factor as a predictor of three-month mortality in patients with liver cirrhosis compared to MELD score.Acta Gastroenterol Belg. 2019; 82: 487-493
- Increased platelet aggregation in patients with decompensated cirrhosis indicates higher risk of further decompensation and death.J Hepatol. 2022; 77: 660-669
- Severity of systemic inflammation is the main predictor of ACLF and bleeding in patients with acutely decompensated cirrhosis.J Hepatol. 2022;
- The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology.J Hepatol. 2020; 73: 842-854
- Global hemostatic profiling in patients with decompensated cirrhosis and bacterial infections.JHEP Rep. 2022; 4100493
Article info
Publication history
Published online: October 22, 2022
Accepted:
October 4,
2022
Received:
September 22,
2022
Identification
Copyright
© 2022 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Clinical significance of substantially elevated von Willebrand factor antigen levels in patients with advanced chronic liver diseaseDigestive and Liver DiseaseVol. 54Issue 10
- PreviewVon Willebrand factor antigen (VWF) is a non-invasive marker for clinically significant portal hypertension (HVPG≥10 mmHg) and confers HVPG-independent prognostic information. While quantification of increased VWF-levels is not relevant in the context of von Willebrand disease, highly elevated VWF may be of clinical significance in ACLD. Thus, we have modified our analytical approach to quantify very high VWF-levels (i.e.,>420%) and investigated their prognostic value.
- Full-Text
- Preview
- Reply to comment: Von Willebrand factor measurement during acute decompensationDigestive and Liver DiseaseVol. 55Issue 1
- PreviewWe would like to thank Dr. Zanetto and colleagues for their interest in our work and for sharing their valuable findings in regard to plasma von Willebrand factor antigen (VWF:Ag) levels in patients with acute decompensation (AD) and their lack of association with acute-on-chronic liver failure (ACLF) development and death [1].
- Full-Text
- Preview
